statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Enlivex Therapeutics (ENLV) has released an update. Enlivex Therapeutics Ltd., a company working on therapeutic candidates, has reportedly maintain...

Enlivex Therapeutics' Stable Financial Outlook

ORLANDO, FL / ACCESSWIRE / March 22, 2024 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (Nasdaq:ENLV) and Unusual Machines Inc. (NYSE American:UMAC) on the RedChip Small...

Enlivex Therapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Check out Jefferies Group Stock Picks &raquo;

 Download GuruFolio Report of Jefferies Group (Updated on 02/28/2024)Related Stocks: FRA:1BT...

Enlivex Therapeutics Ltd at Jefferies Healthcare Conference Transcript

Enlivex Therapeutics Ltd at Robert W Baird Global Healthcare Conference Transcript

Enlivex Therapeutics Ltd at H C Wainwright Global Investment Conference Transcript

NES-ZIONA, ISRAEL / ACCESSWIRE / February 26, 2024 / As we age, our knees start aching for reasons we can't quite pinpoint. Medicines temporarily decrease pain but don't help with the inflammatory...

Enlivex Receives Regulatory Authorization From Israel's Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis

NES-ZIONA, ISRAEL / ACCESSWIRE / February 21, 2024 / Mike Williams made a name for himself making difficult endzone catches for the Tampa Bay Buccaneers. Around the corner from the stadium where he...

Enlivex Completes Enrollment Of All 120 Patients In Phase 2 Trial Of Allocetra In Patients With Sepsis, Third-Leading Cause Of Mortality In US Hospitals

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Enlivex Therapeutics receives IMOH regulatory authorization

Second study of Allocetra in knee osteoarthritis, following the on-going Phase I/II trial in pre-surgery, end-stage osteoarthritis, that is continuing to enroll patients Nes-Ziona, Israel...

Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis

Enlivex Therapeutics (NASDAQ:ENLV  Get Free Report) and G1 Therapeutics (NASDAQ:GTHX  Get Free Report) are both small-cap medical companies, but which is the better stock? We will...

Enlivex Therapeutics (NASDAQ:ENLV) vs. G1 Therapeutics (NASDAQ:GTHX) Financial Analysis

Enlivex Therapeutics Ltd. engages in the development of macrophage reprogramming immunotherapy products. It focuses on the development of Allocetra, a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The company was founded by Dror Mevorach on January 22, 2012 and is headquartered in Ness Ziona, Israel.

Volume	75,057.00
52-Wk High	$4.59
52-Wk Low	$1.15

ENLV Enlivex Therapeutics Ltd

About

Feed

News

Sentiment

Fundamentals